Key Takeaways Novel in vivo CRISPR-based therapy lonvoguran ziclumeran (lonvo-z) dramatically lowered hereditary angioedema (HAE) attack frequency in the HAELO randomized trial.
Crystal Phend is a Medical Journalist and Editor at Medscape. She specializes in various aspects of medicine and healthcare, with a focus on topics such as surgery, telehealth, immunology, hematology, oncology, and digital health. Crystal's insightful work has been featured in prominent outlets including MedPage Today, Knowledia, and MSN.








